Pharmacokinetics can predict the treatment results of irinotecan program
Currently, pharmacogenomics is considered as the most promising applied research. It can predict the clinical therapeutic efficacy and toxicity. Recently, studies show that the body disposal process of topoisomerase I inhibitor irinotecan is determined by the pharmacogenetics. And the pharmacogenomics features can predict the risk of serious toxicity on patients. But it can not explain all the reported toxicity or alleviation situation of irinotecan therapy on tumors. In fact, irinotecan price is reasonable and can be accepted by publics. So it has widely application in pharmaceutical field.
An in vitro study
finds that the proteins of TOP1, ADPRT, TDP1, CDC
The results show
that the incidence of TOP1 IVS4 +61 genotype and neutropenia related and TDP1
IVS12 +79 genotype and objective response rate. TOP1 IVS4 +61 AG + GG genotype
compared with patients with AA-type survival was significantly prolonged, while
the ADPRT +852 (A
The experiment is the first pharmacogenetics study for irinotecan effect factors. Studies from pharmaceutical raw materials suppliers have shown that the difference between TOP1 and ADPRT may change risk of getting neutropenia on patients. Differences among TOP1, TDP1, ADPRT and XRCC1 may affect the efficacy of platinum-based therapy.Source:http://www.cospcn.com